All In Biotech

NDA 019700 · Abbvie

Acular

Ketorolac Tromethamine · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Nov 9, 1992

Approved uses

4

Original approval plus efficacy supplements

Registered trials

238

46 Phase 3, 16 recruiting

FAERS reports

5,005

2,966 serious, 295 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 8, 2025.

ACULAR is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. ACULAR is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. ACULAR is a nonsteroidal anti-inflammatory drug (NSAID) indicated for: The temporary relief of ocular itching due to seasonal allergic conjunctivitis. ( 1 ) The treatment of inflammation following cataract surgery. ( 1 )

Mechanism: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 8, 2002 Supplement 19 · Efficacy LetterReviewLabel
  • Dec 31, 1996 Supplement 7 · Efficacy
  • Sep 18, 1996 Supplement 3 · Efficacy
  • Nov 9, 1992 Original approval · Type 3 - New Dosage Form
1 products under this application
  • ACULAR · KETOROLAC TROMETHAMINE 0.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Ketorolac Tromethamine" as an intervention, any sponsor and status, largest first.

All 238 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective535
  • drug hypersensitivity325
  • nausea276
  • headache267
  • pain265
  • fatigue251
  • dyspnoea240
  • treatment failure211
  • off label use186
  • eye pain183
  • vomiting177
  • diarrhoea164

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200459
200596
200690
200780
2008105
2009129
2010119
2011178
2012210
201381
2014111
2015117
2016378
2017244
2018226
2019320
2020512
2021245
2022323
2023381
2024363
2025376
2026262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Acular (Ketorolac Tromethamine)

2024 spending

$44K

Beneficiaries

102

157 claims

Per beneficiary

$433

$42.23 per unit

View as table
YearSpending
2020$92,185
2021$64,616
2022$48,976
2023$74,908
2024$44,134

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 282 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.